Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: New paradigms

Research output: Contribution to journalReview article

Abstract

Although the outcomes for adults with acute lymphoblastic leukemia (ALL) lag behind the stunningly successful results seen in children, new paradigms and new discoveries bring hope that this disparity will steadily lessen. The adoption of the use of pediatric intensity-type regimens in adolescents and young adults show promise in improving outcomes in this population. Recent donor-versus-no-donor comparisons in the allogeneic transplant setting highlight a potent graft-versusleukemia effect in ALL, and the application of reduced intensity conditioning transplants may exploit this effect while reducing nonrelapse mortality. New therapeutic targets, such as CD22 in precusor B-cell ALL and mutations in NOTCH1 in T-cell ALL, are being exploited in clinical trials. Finally, use of molecular techniques and flow cytometry to quantitate minimal residual disease will allow further stratifications of patients by risk, identification of new therapeutic targets and will lessen drug toxicity through the use of pharmacogenomics.

Original languageEnglish (US)
Pages (from-to)1039-1050
Number of pages12
JournalFuture Oncology
Volume5
Issue number7
DOIs
StatePublished - 2009

Fingerprint

Philadelphia Chromosome
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Transplants
Tissue Donors
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Pharmacogenetics
Residual Neoplasm
Drug-Related Side Effects and Adverse Reactions
Young Adult
Flow Cytometry
B-Lymphocytes
Therapeutics
Clinical Trials
Pediatrics
Mutation
Mortality
Population

Keywords

  • Acute lymphoblastic leukemia
  • Adolescents
  • Blood and marrow transplantation
  • Graft-versus-leukemia effect
  • Minimal residual disease
  • Pharmacogenomics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults : New paradigms. / Litzow, Mark R.

In: Future Oncology, Vol. 5, No. 7, 2009, p. 1039-1050.

Research output: Contribution to journalReview article

@article{4095d8469a804aac80aa0a31aec06adf,
title = "Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: New paradigms",
abstract = "Although the outcomes for adults with acute lymphoblastic leukemia (ALL) lag behind the stunningly successful results seen in children, new paradigms and new discoveries bring hope that this disparity will steadily lessen. The adoption of the use of pediatric intensity-type regimens in adolescents and young adults show promise in improving outcomes in this population. Recent donor-versus-no-donor comparisons in the allogeneic transplant setting highlight a potent graft-versusleukemia effect in ALL, and the application of reduced intensity conditioning transplants may exploit this effect while reducing nonrelapse mortality. New therapeutic targets, such as CD22 in precusor B-cell ALL and mutations in NOTCH1 in T-cell ALL, are being exploited in clinical trials. Finally, use of molecular techniques and flow cytometry to quantitate minimal residual disease will allow further stratifications of patients by risk, identification of new therapeutic targets and will lessen drug toxicity through the use of pharmacogenomics.",
keywords = "Acute lymphoblastic leukemia, Adolescents, Blood and marrow transplantation, Graft-versus-leukemia effect, Minimal residual disease, Pharmacogenomics",
author = "Litzow, {Mark R}",
year = "2009",
doi = "10.2217/fon.09.74",
language = "English (US)",
volume = "5",
pages = "1039--1050",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults

T2 - New paradigms

AU - Litzow, Mark R

PY - 2009

Y1 - 2009

N2 - Although the outcomes for adults with acute lymphoblastic leukemia (ALL) lag behind the stunningly successful results seen in children, new paradigms and new discoveries bring hope that this disparity will steadily lessen. The adoption of the use of pediatric intensity-type regimens in adolescents and young adults show promise in improving outcomes in this population. Recent donor-versus-no-donor comparisons in the allogeneic transplant setting highlight a potent graft-versusleukemia effect in ALL, and the application of reduced intensity conditioning transplants may exploit this effect while reducing nonrelapse mortality. New therapeutic targets, such as CD22 in precusor B-cell ALL and mutations in NOTCH1 in T-cell ALL, are being exploited in clinical trials. Finally, use of molecular techniques and flow cytometry to quantitate minimal residual disease will allow further stratifications of patients by risk, identification of new therapeutic targets and will lessen drug toxicity through the use of pharmacogenomics.

AB - Although the outcomes for adults with acute lymphoblastic leukemia (ALL) lag behind the stunningly successful results seen in children, new paradigms and new discoveries bring hope that this disparity will steadily lessen. The adoption of the use of pediatric intensity-type regimens in adolescents and young adults show promise in improving outcomes in this population. Recent donor-versus-no-donor comparisons in the allogeneic transplant setting highlight a potent graft-versusleukemia effect in ALL, and the application of reduced intensity conditioning transplants may exploit this effect while reducing nonrelapse mortality. New therapeutic targets, such as CD22 in precusor B-cell ALL and mutations in NOTCH1 in T-cell ALL, are being exploited in clinical trials. Finally, use of molecular techniques and flow cytometry to quantitate minimal residual disease will allow further stratifications of patients by risk, identification of new therapeutic targets and will lessen drug toxicity through the use of pharmacogenomics.

KW - Acute lymphoblastic leukemia

KW - Adolescents

KW - Blood and marrow transplantation

KW - Graft-versus-leukemia effect

KW - Minimal residual disease

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=73349116601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349116601&partnerID=8YFLogxK

U2 - 10.2217/fon.09.74

DO - 10.2217/fon.09.74

M3 - Review article

C2 - 19792972

AN - SCOPUS:73349116601

VL - 5

SP - 1039

EP - 1050

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 7

ER -